Novartis raised its combined peak-sales forecast for three drugs to $18 billion from $14 billion, according to its November 19, 2026 update. The higher estimate covers multiple sclerosis treatment Kesimpta, leukemia treatment Scemblix and cholesterol drug Leqvio.
CEO Vas Narasimhan attributed the increase chiefly to commercial performance. He pointed to growing market share for Kesimpta and Scemblix and strong demand for Leqvio in the U.S. and Asia.
The Swiss drugmaker also projected annual sales growth of 5% through 2031. Its previous guidance was 5% to 6% through 2030, though the two forecasts cover different five-year periods. Narasimhan said the new outlook accounts for expected U.S. generic competition for breast cancer drug Kisqali in the second half of 2031.
Citi analysts said the 2031 sales guidance was about 3% above consensus, but expected investors to remain skeptical about growth after 2031 until more pipeline data becomes available. Novartis shares were down 2.4% in mid-morning trading in Switzerland on the day of the update.
Recent trial results have added to those questions. In September, a trial of cardiovascular drug pelacarsen failed to show improved cardiovascular outcomes. The following day, del-desiran, an experimental treatment for a muscle-wasting disorder, failed in a late-stage trial; Novartis shares fell nearly 11%, their biggest one-day decline since 1987. Narasimhan defended the company’s acquisition strategy following the del-desiran result. Novartis had acquired the drug through its $12 billion deal for Avidity Biosciences earlier in 2026.

